BD enters into an agreement with AITbiotech Pte Ltd for the distribution of AITbiotech abTES™ BM qPCR assays optimized on the BD MAX™ System
BD has announced through its Singapore-based subsidiary, Becton Dickinson Holdings Pte Ltd, the signing of a distribution agreement with AITbiotech Pte Ltd, a leading manufacturer of molecular diagnostic (MDx) assays and provider of genomic services based in Singapore, for the distribution of AITbiotechabTES™ BM qPCR assays in the Asia Pacific region.
“Our agreement with AITbiotech represents a key milestone in BD’s strategy to make the BD MAX™ System an indispensable laboratory tool that empowers laboratory professionals to provide rapid and accurate test results,” said Glen Costin, Business Director Molecular & Cancer Diagnostics Asia Pacific, BD Diagnostics. “The fully automated BD MAX™ System has a content-rich menu with a flexible open mode capability and standardized workflows that enable laboratories to consolidate a broad range of molecular tests that meet both their current and future needs.”
AITbiotech abTES™ BM assays are developed to optimize applications on the BD MAX™ System. The abTES™ BM assays are manufactured at AITbiotech’s ISO13485 certified facilities in Singapore. At present, abTES™ BM Research Use Only assays are available for detection of Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG), Herpes Simplex Virus 1/Herpes Simplex Virus 2/Varicella Zoster Virus (HSV1/2/VZV) and Mycobacterium tuberculosis (MTB).
“We are extremely excited about the opportunity to work with a leading global MDx company like BD,” said Alex Thian, AITbiotech CEO. “AITbiotech, sees the opportunity to work with BD and its unique fully automated BD MAX™ System as a great way to expand our assay offering.”Go back